Interleukin-1 receptor-associated kinase 1 (IRAK-1) is downstream from IL-1 receptors and TLRs. We identified IRS-1 (pSer24) as the first physiological substrate for IRAK-1. Decreased binding of IRS-1 (pS24) to PI 3-kinase impairs insulin action. IRAK-1 k/o mice have improved metabolic insulin action. Currently unknown is the relevance of IRAK-1/IRS-1 interactions to human pathophysiology. To investigate this topic, we examined human skeletal muscle (SkM) from NGT (n=10), IGT (n=6), and T2D (n=12) (1st cohort). Fasting protein expression of IRAK-1 and phospho-IRAK-1 (p-IRAK-1, activity proxy) and IRS-1 (pS24) did not differ significantly across groups. Insulin infusion during hyperinsulinemic glucose clamp (HGC), caused acute reductions in IRS-1 (pS24) in NGT that was diminished in IGT, and absent in T2D (p < 0.05, vs. NGT). p-IRAK-1 was unaltered during HGC in 1st cohort. Acute insulin-induced reduction of IRS-1 (pS24) in SkM was also found in women with PCOS (2nd cohort, n=12). Insulin sensitivity improved after pioglitazone treatment (pio, 6 mo). This was associated with reduction in IRS-1 (pS24) (both fasting and HGC (acute insulin stimulation); (vs. pio pre-treatment). In a 3rd cohort, nondiabetic (n=13) and T2D subjects (n=13), associations between IRAK-1 phosphorylation in the fasting state and measures of insulin sensitivity were noted: HOMA-IR (r=0.57, p=0.01; consistent with HGC data from PCOS pre- and post-pio, and trend in 1st cohort). In sum: 1) p-IRAK-1 in SkM (activity surrogate), predicts insulin resistance (IR) in human subjects. 2) Ability of acute insulin stimulation to reduce IRS-1 (pS24) is absent in T2D and improved after pio intervention in PCOS. 3) Changes in IRAK-1 phosphorylation of IRS-1 (S24) represents cross-talk between immune signaling and insulin signaling that may cause IR in human SkM. Our findings suggest that IRS-1 (pS24) and p-IRAK-1 are biomarkers of IR that may be molecular targets for therapy of IR in human metabolic diseases.

Disclosure

T.P. Ciaraldi: None. S. Mudaliar: Advisory Panel; Self; AstraZeneca. Speaker's Bureau; Self; AstraZeneca. Research Support; Self; Janssen Pharmaceuticals, Inc., Intarcia Therapeutics, Inc., National Institutes of Health. L. Li: None. R. Scalia: None. X. Sun: None. R.R. Henry: Consultant; Self; Abbott, Alere Inc., AstraZeneca. Research Support; Self; AstaReal. Advisory Panel; Self; Boehringer Ingelheim Pharmaceuticals, Inc.. Consultant; Self; Bristol-Myers Squibb Company. Advisory Panel; Self; Elcelyx Therapeutics, Inc.. Research Support; Self; Eli Lilly and Company, Hitachi, Ltd.. Advisory Panel; Self; AstraZeneca. Consultant; Self; Boehringer Ingelheim Pharmaceuticals, Inc.. Advisory Panel; Self; Intarcia Therapeutics, Inc.. Consultant; Self; Intarcia Therapeutics, Inc., Ionis Pharmaceuticals, Inc., Janssen Pharmaceuticals, Inc.. Advisory Panel; Self; Johnson & Johnson Services, Inc.. Research Support; Self; Lexicon Pharmaceuticals, Inc.. Consultant; Self; Ligand Pharmaceuticals, Inc.. Advisory Panel; Self; Merck & Co., Inc.. Consultant; Self; Merck & Co., Inc.. Research Support; Self; Viacyte, Inc.. Consultant; Self; Sanofi-Aventis. Advisory Panel; Self; Sanofi-Aventis. M. Quon: None.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.